Targeting cancer-derived adenosine: new therapeutic approaches.
Identifieur interne : 000914 ( Main/Exploration ); précédent : 000913; suivant : 000915Targeting cancer-derived adenosine: new therapeutic approaches.
Auteurs : Arabella Young ; Deepak Mittal ; John Stagg [Canada] ; Mark J. Smyth [Australie]Source :
- Cancer discovery [ 2159-8290 ] ; 2014.
English descriptors
- KwdEn :
- 5'-Nucleotidase (antagonists & inhibitors), 5'-Nucleotidase (immunology), Adenosine (immunology), Adenosine (metabolism), Animals, Antigens, CD (immunology), Apyrase (antagonists & inhibitors), Apyrase (immunology), GPI-Linked Proteins (antagonists & inhibitors), GPI-Linked Proteins (immunology), Humans, Immunosuppressive Agents (therapeutic use), Mice, Molecular Targeted Therapy, Neoplasms (drug therapy), Neoplasms (immunology), Neoplasms (pathology), Purinergic P1 Receptor Antagonists.
- MESH :
- chemical , antagonists & inhibitors : 5'-Nucleotidase, Apyrase, GPI-Linked Proteins.
- chemical , immunology : 5'-Nucleotidase, Adenosine, Antigens, CD, Apyrase, GPI-Linked Proteins.
- chemical , metabolism : Adenosine.
- chemical , therapeutic use : Immunosuppressive Agents.
- drug therapy : Neoplasms.
- immunology : Neoplasms.
- pathology : Neoplasms.
- Animals, Humans, Mice, Molecular Targeted Therapy, Purinergic P1 Receptor Antagonists.
Abstract
CD73 generation of immunosuppressive adenosine within the hypoxic tumor microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor progression, metastases, and poor disease outcomes. Therapies targeted toward the adenosinergic pathway, such as antibodies targeting CD73 and CD39, have proven efficacy in mouse tumor models; however, humanized versions are only in preliminary development. In contrast, A(2A) adenosine receptor antagonists have progressed to late-stage clinical trials in Parkinson disease, yet evidence of their role in oncology is limited. This review will compare the merits and challenges of these therapeutic approaches, identifying tumor indications and combinations that may be fruitful as they progress to the clinic.
DOI: 10.1158/2159-8290.CD-14-0341
PubMed: 25035124
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000701
- to stream PubMed, to step Curation: 000701
- to stream PubMed, to step Checkpoint: 000701
- to stream Ncbi, to step Merge: 001831
- to stream Ncbi, to step Curation: 001831
- to stream Ncbi, to step Checkpoint: 001831
- to stream Main, to step Merge: 000916
- to stream Main, to step Curation: 000914
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeting cancer-derived adenosine: new therapeutic approaches.</title><author><name sortKey="Young, Arabella" sort="Young, Arabella" uniqKey="Young A" first="Arabella" last="Young">Arabella Young</name><affiliation><nlm:affiliation>QIMR Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Mittal, Deepak" sort="Mittal, Deepak" uniqKey="Mittal D" first="Deepak" last="Mittal">Deepak Mittal</name><affiliation><nlm:affiliation>QIMR Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Stagg, John" sort="Stagg, John" uniqKey="Stagg J" first="John" last="Stagg">John Stagg</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>QIMR Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Queensland, Australia; and mark.smyth@qimrberghofer.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>QIMR Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25035124</idno><idno type="pmid">25035124</idno><idno type="doi">10.1158/2159-8290.CD-14-0341</idno><idno type="wicri:Area/PubMed/Corpus">000701</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000701</idno><idno type="wicri:Area/PubMed/Curation">000701</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000701</idno><idno type="wicri:Area/PubMed/Checkpoint">000701</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000701</idno><idno type="wicri:Area/Ncbi/Merge">001831</idno><idno type="wicri:Area/Ncbi/Curation">001831</idno><idno type="wicri:Area/Ncbi/Checkpoint">001831</idno><idno type="wicri:Area/Main/Merge">000916</idno><idno type="wicri:Area/Main/Curation">000914</idno><idno type="wicri:Area/Main/Exploration">000914</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Targeting cancer-derived adenosine: new therapeutic approaches.</title><author><name sortKey="Young, Arabella" sort="Young, Arabella" uniqKey="Young A" first="Arabella" last="Young">Arabella Young</name><affiliation><nlm:affiliation>QIMR Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Mittal, Deepak" sort="Mittal, Deepak" uniqKey="Mittal D" first="Deepak" last="Mittal">Deepak Mittal</name><affiliation><nlm:affiliation>QIMR Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Queensland, Australia; and.</nlm:affiliation><wicri:noCountry code="subField">Australia; and</wicri:noCountry></affiliation></author><author><name sortKey="Stagg, John" sort="Stagg, John" uniqKey="Stagg J" first="John" last="Stagg">John Stagg</name><affiliation wicri:level="1"><nlm:affiliation>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Québec</wicri:regionArea><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name><affiliation wicri:level="1"><nlm:affiliation>QIMR Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Queensland, Australia; and mark.smyth@qimrberghofer.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>QIMR Berghofer Medical Research Institute; School of Medicine, University of Queensland, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author></analytic><series><title level="j">Cancer discovery</title><idno type="eISSN">2159-8290</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5'-Nucleotidase (antagonists & inhibitors)</term><term>5'-Nucleotidase (immunology)</term><term>Adenosine (immunology)</term><term>Adenosine (metabolism)</term><term>Animals</term><term>Antigens, CD (immunology)</term><term>Apyrase (antagonists & inhibitors)</term><term>Apyrase (immunology)</term><term>GPI-Linked Proteins (antagonists & inhibitors)</term><term>GPI-Linked Proteins (immunology)</term><term>Humans</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Mice</term><term>Molecular Targeted Therapy</term><term>Neoplasms (drug therapy)</term><term>Neoplasms (immunology)</term><term>Neoplasms (pathology)</term><term>Purinergic P1 Receptor Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>5'-Nucleotidase</term><term>Apyrase</term><term>GPI-Linked Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>5'-Nucleotidase</term><term>Adenosine</term><term>Antigens, CD</term><term>Apyrase</term><term>GPI-Linked Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adenosine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Mice</term><term>Molecular Targeted Therapy</term><term>Purinergic P1 Receptor Antagonists</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">CD73 generation of immunosuppressive adenosine within the hypoxic tumor microenvironment causes dysregulation of immune cell infiltrates, resulting in tumor progression, metastases, and poor disease outcomes. Therapies targeted toward the adenosinergic pathway, such as antibodies targeting CD73 and CD39, have proven efficacy in mouse tumor models; however, humanized versions are only in preliminary development. In contrast, A(2A) adenosine receptor antagonists have progressed to late-stage clinical trials in Parkinson disease, yet evidence of their role in oncology is limited. This review will compare the merits and challenges of these therapeutic approaches, identifying tumor indications and combinations that may be fruitful as they progress to the clinic.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Canada</li></country></list><tree><noCountry><name sortKey="Mittal, Deepak" sort="Mittal, Deepak" uniqKey="Mittal D" first="Deepak" last="Mittal">Deepak Mittal</name><name sortKey="Young, Arabella" sort="Young, Arabella" uniqKey="Young A" first="Arabella" last="Young">Arabella Young</name></noCountry><country name="Canada"><noRegion><name sortKey="Stagg, John" sort="Stagg, John" uniqKey="Stagg J" first="John" last="Stagg">John Stagg</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000914 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000914 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25035124
|texte= Targeting cancer-derived adenosine: new therapeutic approaches.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25035124" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |